Monopar Announces Timeline of Upcoming Data Events for Validive, Camsirubicin, and MNPR-202
10/27/2022 - 08:00 AM
WILMETTE, Ill., Oct. 27, 2022 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, will be presenting clinical data on camsirubicin and preclinical data on MNPR-202 in November and December, and is planning to report out the interim go/no-go analysis for its Validive Phase 2b/3 VOICE trial in Q1 2023.
November 2022:
Poster of Camsirubicin Phase 1b Clinical Trial Data to be Presented at CTOS 2022
Event: Connective Tissue Oncology Society (CTOS) Annual Meeting Conference Date: November 16-19, 2022 Location: Vancouver Convention Centre, Vancouver, BC, Canada
December 2022:
Poster of MNPR-202 Preclinical Data to be Presented at ASH 2022
Event: 64th American Society of Hematology (ASH) Annual Meeting & Exposition Date: December 10-13, 2022 Location: Ernest N. Morial Convention Center, New Orleans, Louisiana
Q1 2023:
Interim go/no-go Analysis for Validive Phase 2b/3 VOICE Clinical Trial
The Company plans to report out the interim go/no-go decision for its Validive Phase 2b/3 VOICE clinical trial in Q1 2023. All patients required for the interim analysis have been enrolled. Patient enrollment will continue, as will adding additional clinical sites (currently 71 sites across the U.S. and Europe), in preparation for a potentially positive interim analysis.
About Monopar Therapeutics Inc.
Monopar Therapeutics is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. Monopar's pipeline consists of Validive® (Phase 2b/3) for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin (Phase 1b) for the treatment of advanced soft tissue sarcoma; a late-stage preclinical antibody, MNPR-101, for advanced cancers and severe COVID-19; and an early-stage camsirubicin analog, MNPR-202, for various cancers. For more information, visit: www.monopartx.com .
CONTACT:
Monopar Therapeutics Inc. Investor Relations Kim R. Tsuchimoto Chief Financial Officer kimtsu@monopartx.com
Follow Monopar on social media for updates: Twitter: @MonoparTx LinkedIn: Monopar Therapeutics
MNPR Rankings
N/A Ranked by Stock Gains
MNPR Stock Data
Industry
Research and Development in Biotechnology
Sector
Professional, Scientific, and Technical Services
Tags
Health Technology, Biotechnology
Country
US
City
Wilmette
About MNPR
monopar therapeutics inc., a biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the united states. it is involved in developing validive, a clonidine mucobuccal tablet that is in phase iii for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; camsirubicin, a topoisomerase ii-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart; and mnpr-101, a humanized monoclonal antibody for treating advanced solid cancers. the company has a collaboration grupo espaã±ol de investigaciã³n en sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; and northstar medical radioisotopes, llc to develop radio-immuno-therapeutics targeting severe covid-19. monopar therapeutics inc. was founded in 2014 and is headquartered in wilmette, illinois.